OncoMatch/Clinical Trials/NCT03482102
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Is NCT03482102 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tremelimumab and Durvalumab for hepatocellular carcinoma.
Treatment: Tremelimumab · Durvalumab — This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: * Durvalumab * Tremelimumab * Radiation Therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: gemcitabine-based chemotherapy
second line treatment and beyond for cholangiocarcinoma or gemcitabine-based chemotherapy for biliary tract cancer
Cannot have received: immunotherapy (anti-CTLA4, tremelimumab, anti-PD-1, anti-PD-L1, durvalumab)
Prior immunotherapy including but not limited to anti-CTLA4, including tremelimumab anti-PD-1, and anti-PD-L1, including durvalumab
Cannot have received: radiation therapy
Exception: prior irradiation to the planned radiation target lesion
Prior irradiation to the planned radiation target lesion
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dL; ANC ≥ 1.5 x 10^9/L; Platelet count ≥75×10^9/L; INR < 2.0
Kidney function
Calculated creatinine clearance > 40 mL/min as determined by Cockcroft-Gault (using actual body weight)
Liver function
Serum bilirubin ≤2.0× ULN; ALT and AST ≤ 3 x institutional ULN; Albumin > 2.8 g/dL; Child-Pugh Score of A. A score of B7 is allowed without severe ascites or without hepatic encephalopathy.
Cardiac function
Mean QTc < 470 ms using Fredericia's Correction
Adequate organ and marrow function, defined as: Hemoglobin ≥ 9 g/dL; ANC ≥ 1.5 x 10^9/L; Platelet count ≥75×10^9/L; Serum bilirubin ≤2.0× ULN; ALT and AST ≤ 3 x institutional ULN; Albumin > 2.8 g/dL; INR < 2.0; Calculated creatinine clearance > 40 mL/min as determined by Cockcroft-Gault (using actual body weight); Mean QTc < 470 ms using Fredericia's Correction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify